-
公开(公告)号：US20210317224A1
公开(公告)日：2021-10-14
申请号：US17286437
申请日：2020-08-12
Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
Inventor： Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
-
公开(公告)号：US10973853B2
公开(公告)日：2021-04-13
申请号：US16483870
申请日：2019-02-11
Applicant: I-Mab Biopharma US Limited
Inventor： Feifei Cui , Lei Fang , Bingshi Guo , Zhengyi Wang , Jingwu Zang
Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
-
公开(公告)号：US20210054093A1
公开(公告)日：2021-02-25
申请号：US16989702
申请日：2020-08-10
Applicant: I-Mab Biopharma US Limited
Inventor： Zhengyi Wang , Lei Fang , Bingshi Guo , Jingwu Zang
Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
-
公开(公告)号：US20210015858A1
公开(公告)日：2021-01-21
申请号：US16483870
申请日：2019-02-11
Applicant: I-MAB BIOPHARMA US LIMITED
Inventor： Feifei Cui , Lei Fang , Bingshi Guo , Zhengyi Wang , Jingwu Zang
Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
-
公开(公告)号：US20200317789A1
公开(公告)日：2020-10-08
申请号：US16909400
申请日：2020-06-23
Applicant: I-MAB Biopharma US Limited
Inventor： Lei Fang , Zhengyi Wang , Bingshi Guo , Jingwu Zang
IPC: C07K16/28 , A61P31/20 , A61P31/14 , A61P35/00 , A61P35/02 , A61P31/18 , A61P31/22 , A61P31/08 , A61P31/04 , A61P31/06 , A61P31/16 , A61K35/17
Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
-
Patent Agency Ranking
公开(公告)号：US11414485B2
公开(公告)日：2022-08-16
申请号：US16687387
申请日：2019-11-18
Applicant: I-MAB Biopharma US Limited
Inventor： Lei Fang , Zhengyi Wang , Bingshi Guo , Jingwu Zang , Wenqing Jiang , Yongqiang Wang
Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.
-
公开(公告)号：US20220112258A1
公开(公告)日：2022-04-14
申请号：US17278157
申请日：2020-07-27
Applicant: I-Mab Biopharma US Limited
Inventor： Feifei Cui , Lei Fang , Yuanyuan Yang , Zhengyi Wang , Bingshi Guo
Abstract: Provided are polypeptides having an antigen-binding unit targeting a tumor antigen and an IL-7 protein or fragment thereof, fused to a Fc fragment. The disclosed polypeptides can be used for treating cancer.
-
公开(公告)号：US11261259B2
公开(公告)日：2022-03-01
申请号：US17286437
申请日：2020-08-12
Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
Inventor： Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
-
公开(公告)号：US20200347146A1
公开(公告)日：2020-11-05
申请号：US16963091
申请日：2019-07-25
Applicant: I-Mab Biopharma US Limited
Inventor： Zhengyi Wang , Lei Fang , Bingshi Guo , Jingwu Zang , Qiumei Yang
IPC: C07K16/28
Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.
-
公开(公告)号：US12091467B2
公开(公告)日：2024-09-17
申请号：US16989702
申请日：2020-08-10
Applicant: I-Mab Biopharma US Limited
Inventor： Zhengyi Wang , Lei Fang , Bingshi Guo , Jingwu Zang
CPC classification number: C07K16/2896 , A61K47/6803 , A61P35/00 , C07K16/30 , G01N33/6893 , A61K39/395 , C07K2317/56 , C07K2317/569 , G01N2333/70596
Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.019 seconds)
